Skip to product information
1 of 1

GeneBio Systems

Recombinant Human GRK6/GPRK6 Protein (His & GST Tag)

Recombinant Human GRK6/GPRK6 Protein (His & GST Tag)

SKU:PKSH030350

Regular price £617.00 GBP
Regular price Sale price £617.00 GBP
Sale Sold out
Shipping calculated at checkout.

Size: 50μg

Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: GPRK6

Research Areas: Signal Transduction,Cardiovascular

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application: Enzyme

Fusion tag: N-His-GST

UNIProt ID: P43250

Accession: P43250-2

Background: G protein-coupled receptor kinase 6, also known as G protein-coupled receptor kinase GRK6, GRK6 and GPRK6, is a lipid-anchor protein which belongs to theprotein kinase superfamily, AGC Ser/Thr protein kinase family and GPRK subfamily. GRK6 / GPRK6 contains oneAGC-kinase C-terminal domain, oneprotein kinase domain and oneRGS domain. This protein phosphorylates the activated forms of G protein-coupled receptors thus initiating their deactivation. Several transcript variants encoding different isoforms have been described. GRK6 / GPRK6 is widely expressed. GRK6 / GPRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. GRK6 also appears to be involved in responses to morphine. Inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

Concentration:

Activity: The specific activity was determined to be 7 nmol/min/mg using casein as substrate.

Sequence: Met 1-Arg 589

Purity: > 93 % as determined by reducing SDS-PAGE.

Formulation: Supplied as sterile solution of 20mM Tris, 500mM NaCl, 2mM GSH, 0.5mM PMSF, pH 7.4

Reconstitution: Not Applicable

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 95.1 kDa

ObservedMW: 85 kDa

View full details